Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in New Hampshire: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 10 | 288 | 21% |
| 2020 | 10 | 331 | 25% |
| 2021 | 12 | 352 |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 84% of the cases CMS names in New Hampshire; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 191 | 8,988+5.9%/yr | +5.9%/yr | 4.3 | 12% | 14,400 in 2030+8.1%/yr |
| Pennsylvania | 139 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 18 | 814−0.4%/yr | −0.4%/yr | 3.70.8× | 0% | 1,020 in 2030+3.7%/yr |
| EP ablation |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in New Hampshire · Every state · Compare with New York
| 2024 |
| 537 |
| 39% |
| 2025 est. | ≈ 780 | – |
| 2026 est. | ≈ 930 | – |
| 29% |
| 2022 | 13 | 451 | 33% |
| 2023 | 12 | 404 | 37% |
| 2024 | 16 | 537 | 39% |
| 2025 from claims | – | 783 633–920 | 40% |
| 2026 forecast | – | 930 728–1,168 | 35% |
| 2027 forecast | – | 1,039 771–1,374 | 34% |
| 2028 forecast | – | 1,162 823–1,604 | 34% |
| 2029 forecast | – | 1,299 883–1,862 | 33% |
| 2030 forecast | – | 1,451 951–2,154 | 33% |
In 2025, 53% inpatient hospital, 36% hospital outpatient, 11% office. The share outside the hospital has moved +11 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~930 | ~510 | ~320 | ~98 |
| 2027 · ~1,000 | ~570 | ~360 | ~110 |
| 2028 · ~1,200 | ~640 | ~390 | ~120 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 55% (53% in 2025), hospital outpatient about 34% (36% in 2025).
| 4,787+8.9%/yr |
| +8.9%/yr |
| 3.0 |
| 14% |
| 7,520 in 2030+7.8%/yr |
| New Jersey | 90 | 3,940+7.1%/yr | +7.1%/yr | 3.4 | 37% | 6,480 in 2030+8.7%/yr |
| Massachusetts | 67 | 2,548+8.4%/yr | +8.4%/yr | 2.4 | 8% | 4,890 in 2030+11%/yr |
| Connecticut | 35 | 1,043+11%/yr | +11%/yr | 2.7 | 5% | 1,680 in 2030+8.2%/yr |
| Maine | 13 | 319+15%/yr | +15%/yr | 1.7 | 0% | 450 in 2030+5.7%/yr |
| Rhode Island | 5 | 246−0.3%/yr | −0.3%/yr | 2.3 | 0% | 350 in 2030+6.1%/yr |
| Vermont | 3 | 103−6.7%/yr | −6.7%/yr | 0.8 | 0% | 200 in 2030+12%/yr |
| 11 |
| 595+16%/yr |
| +16%/yr |
| 2.30.7× |
| 0% |
| 1,590 in 2030+18%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 76% of company spending on these surgeons in 2025, −11 pts on 2024.
In 2025, 4 companies reported engagement with New Hampshire’s surgeons worth $58K in consulting, speaking, meals and travel tied to these products, about $3,594 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.